New immune cell therapy targets advanced prostate cancer that has stopped responding to standard treatments
NCT ID NCT06236139
Summary
This trial tests whether a new type of cell therapy (STEAP1 CART) combined with the hormone drug enzalutamide can help control advanced prostate cancer that has spread and stopped responding to standard treatments. The study will enroll 48 men whose cancer has progressed despite multiple prior therapies. Researchers will first determine the safest dose of the engineered immune cells, then assess whether the combination treatment can shrink tumors and control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.